By Lori Solomon HealthDay ReporterFRIDAY, June 20, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...

Biotech stock KalVista has soared recently, as the firm looks to fundamentally change the treatment landscape for HAE ...

The U.S. Food and Drug Administration (FDA) has approved ANDEMBRY® (garadacimab-gxii), developed by CSL, as the first ...

The biotech industry faces a mix of longstanding and novel political challenges amid President Donald Trump’s second term.

BioCryst Pharmaceuticals (BCRX) announced that ORLADEYO (berotralstat) has been approved for national reimbursement in the Netherlands for routine prevention of hereditary angioedema (HAE) attacks in ...

These interim findings suggest berotralstat may help children with HAE experience fewer symptoms and a more normal daily life. Berotralstat for the Prevention of Hereditary Angioedema Attacks ...

(Nasdaq: BCRX) today announced new data which highlights the reduction in the percentage of days with hereditary angioedema (HAE) symptoms among young children initiating berotralstat in the APeX ...

RESEARCH TRIANGLE PARK, N.C., May 30, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new data which highlights the reduction in the percentage of days with ...

today announced new data which highlights the reduction in the percentage of days with hereditary angioedema (HAE) symptoms among young children initiating berotralstat in the APeX-P trial ...

today announced new data which highlights the reduction in the percentage of days with hereditary angioedema (HAE) symptoms among young children initiating berotralstat in the APeX-P trial, and the ...